Large-scale testing (Phase 3)Ended earlyNCT02108951
What this trial is testing
Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Who this might be right for
Philidelphia Positive Chronic Myeloid Leukaemia
Novartis Pharmaceuticals 20